Skip to content

Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh

Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00198822
Enrollment
59666
Registered
2005-09-20
Start date
2001-08-31
Completion date
2008-03-31
Last updated
2012-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infant Mortality, Maternal Mortality, Vitamin A Deficiency

Keywords

Maternal mortality, Infant mortality, Vitamin A, Beta-carotene, Micronutrients, Bangladesh, Neonatal mortality

Brief summary

The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.

Detailed description

Maternal mortality and vitamin A deficiency coexist in rural South Asia. In Nepal, weekly supplementation with vitamin A or beta-carotene during the child-bearing years reduced all-cause maternal mortality and, in night blind women, also infant mortality. The present trial is testing the efficacy of the same supplements from \ 9 weeks' gestation to 12 weeks postpartum. The planned sample size is 68,000 pregnancies. It is being conducted in 19 rural unions, covering an area of \ 750 sq km with a population of \ 580,000 in Gaibandha and Southern Rangpur Districts in Northern Bangladesh. The study area was mapped as 596 sectors (unit of randomization), each comprising 200-275 households; \ 135,000 houses were numerically addressed and, at the outset, 103,000 women were listed. Women are visited at home every 5 weeks by 596 trained female staff to detect pregnancy by a combination of menstrual history and urine testing. Newly married women are prospectively enlisted for pregnancy surveillance. Following informed consent urine-positive (pregnant) women detected during surveillance are enrolled to receive weekly a capsule containing 7000 retinol equivalents of preformed vitamin A, 42 mg of beta-carotene or placebo. Vital events are recorded weekly through 3 months postpartum. Trained interviewers conduct maternal nutritional and health and household socioeconomic assessments in the 1st trimester. At 3 months postpartum, interviewers assess both mother and infant for health and nutritional status, including apparent birth defects that are later physician-confirmed. An additional home health assessment occurs at 6 months post partum, and vital status is recorded for mother and infant at one year postpartum. A \ 3% subsample of enrolled pregnant women participate in a substudy involving enhanced clinical, anthropometric, biochemical, body compositional, morbidity and interview-based assessment protocols in the 1st, 2nd and 3rd trimesters, and at 3 months post-partum. Reported maternal and infant deaths are verified and causes ascertained during verbal autopsy interviews with family members of the deceased.

Interventions

DIETARY_SUPPLEMENTVitamin A or Beta-Carotene Supplements

weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy

Sponsors

United States Agency for International Development (USAID)
CollaboratorFED
Bill and Melinda Gates Foundation
CollaboratorOTHER
Canadian International Development Agency
CollaboratorOTHER_GOV
The Sight and Life Research Institute
CollaboratorUNKNOWN
Access Business Group
CollaboratorINDUSTRY
Johns Hopkins Bloomberg School of Public Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
15 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* Married women of reproductive age * First pregnancy during time period of trial

Exclusion criteria

* Premenarchial girls * Married women with a previous pregnancy enrolled into the trial * Previously married women who have moved into the study area * Single women (never married, widowers) * Women who are sterilized (or whose husbands are sterilized) * Menopausal women

Design outcomes

Primary

MeasureTime frameDescription
All-cause, Pregnancy-related MortalityDeaths during pregnancy through 12 weeks postpartumMortality evaluated on intent-to-treat basis

Secondary

MeasureTime frame
Maternal Morbidity, Including Obstetric Complicationsthrough the 1st 24 weeks following termination of pregnancy
Gestational Age at Birthwithin 24 weeks after birth
Fetal Growth and Postnatal Infant Growth Through Three Months of Agethrough the 1st 12 weeks after birth
All-cause 3-month Infant MortalityDeaths through the 1st 12 weeks of life
Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother)Third trimester of pregnancy (about the 32nd week of gesatation)
Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother)Third trimester of pregnancy (about the 32nd week of gestation)
Infant Morbidity Through 3 Months of Agewithin 24 weeks after birth

Countries

Bangladesh, United States

Participant flow

Recruitment details

Women were recruited into the trial from August 2001 to January 2007. As this was a community trial, we identified pregnant women by conducting a urine test on women reporting to be amenstrual from the last visit during 5 weekly visit cycles to their homes in rural communities of the districts of Rangpur and Gaibandha, Bangladesh.

Participants by arm

ArmCount
1 Placebo Control
Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy
19,862
2 Vitamin A Supplement
Weekly oral supplement with 7000 micrograms of retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy
19,806
3 Beta-Carotene Group
Weekly oral supplement with 42 mg of all-trans beta-carotene from early pregnancy through 12 weeks following termination of pregnancy
19,998
Total59,666

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyLost to Follow-up142021

Baseline characteristics

Characteristic2 Vitamin A Supplement3 Beta-Carotene Group1 Placebo ControlTotal
Age Categorical
<=18 years
5774 participants5936 participants5875 participants17585 participants
Age Categorical
>=65 years
0 participants0 participants0 participants0 participants
Age Categorical
Between 18 and 65 years
14017 participants14056 participants13973 participants42046 participants
Age Continuous23.17 years
STANDARD_DEVIATION 6.56
23.06 years
STANDARD_DEVIATION 6.56
23.03 years
STANDARD_DEVIATION 6.53
23.09 years
STANDARD_DEVIATION 6.55
Region of Enrollment
Bangladesh
19806 participants19998 participants19862 participants59666 participants
Sex: Female, Male
Female
19806 Participants19998 Participants19862 Participants59666 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 00 / 00 / 0
serious
Total, serious adverse events
0 / 00 / 00 / 0

Outcome results

Primary

All-cause, Pregnancy-related Mortality

Mortality evaluated on intent-to-treat basis

Time frame: Deaths during pregnancy through 12 weeks postpartum

Population: As the study ended on the advice of the Data and Safety Monitoring Board, based on evidence of no difference, all enrolled women who had a chance of being followed through 84 days after the end of their pregnancy were included in the trial. The cohort included pregnancies identified between August 17, 2001 and January 5, 2006.

ArmMeasureValue (NUMBER)
1 Placebo ControlAll-cause, Pregnancy-related Mortality41 Participants
2 Vitamin A SupplementAll-cause, Pregnancy-related Mortality47 Participants
3 Beta-Carotene GroupAll-cause, Pregnancy-related Mortality50 Participants
Comparison: Sample size was based on an expected placebo group MR of 600/100,000 pregnancies, requiring 18,000 pregnancies to detect a 35% reduction in all-cause mortality, with a 5% type I error, 80% power, 1.21 design effect, 15% early pregnancy loss and 10% loss to follow-up. A mid-study DSMB analysis suggested a lower MR, leading the SS to be increased to 67,740. However, with no mortality difference evident at a DSMB meeting in Dec 2006, the trial was halted leaving 59,721 in the trial cohort.p-value: 0.05generalized estimating equations
Secondary

All-cause 3-month Infant Mortality

Time frame: Deaths through the 1st 12 weeks of life

Population: Mortality evaluated on intent-to-treat basis

ArmMeasureValue (NUMBER)
1 Placebo ControlAll-cause 3-month Infant Mortality951 participants
2 Vitamin A SupplementAll-cause 3-month Infant Mortality904 participants
3 Beta-Carotene GroupAll-cause 3-month Infant Mortality979 participants
Secondary

Fetal Growth and Postnatal Infant Growth Through Three Months of Age

Time frame: through the 1st 12 weeks after birth

Secondary

Gestational Age at Birth

Time frame: within 24 weeks after birth

Secondary

Infant Morbidity Through 3 Months of Age

Time frame: within 24 weeks after birth

Secondary

Maternal Morbidity, Including Obstetric Complications

Time frame: through the 1st 24 weeks following termination of pregnancy

Secondary

Plasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother)

Time frame: Third trimester of pregnancy (about the 32nd week of gesatation)

ArmMeasureValue (MEAN)Dispersion
1 Placebo ControlPlasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother)0.11 Plasma beta-carotene micromoles / literStandard Deviation 0.09
2 Vitamin A SupplementPlasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother)0.12 Plasma beta-carotene micromoles / literStandard Deviation 0.12
3 Beta-Carotene GroupPlasma Beta-carotene in the Third Trimester of Pregnancy(Nutritonal Status of the Mother)0.12 Plasma beta-carotene micromoles / literStandard Deviation 0.1
Secondary

Plasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother)

Time frame: Third trimester of pregnancy (about the 32nd week of gestation)

ArmMeasureValue (MEAN)Dispersion
1 Placebo ControlPlasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother)1.02 micromoles per literStandard Deviation 0.31
2 Vitamin A SupplementPlasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother)1.25 micromoles per literStandard Deviation 0.33
3 Beta-Carotene GroupPlasma Retinol at the Third Trimester of Pregnancy (Nutritional Status of the Mother)1.06 micromoles per literStandard Deviation 0.33

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026